Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
4.450
-0.175 (-3.78%)
At close: Oct 10, 2025, 4:00 PM EDT
4.340
-0.110 (-2.47%)
After-hours: Oct 10, 2025, 6:37 PM EDT

Kalaris Therapeutics Stock Forecast

KLRS's stock price has decreased by -76.13% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Kalaris Therapeutics stock has a target of 23, which predicts a 416.85% increase from the current stock price of 4.45.

Price Target: $23 (+416.85%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$23$23$23$23
Change+416.85%+416.85%+416.85%+416.85%
* Price targets were last updated on Sep 3, 2025.

Analyst Ratings

The average analyst rating for Kalaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingAug '25Sep '25Oct '25
Strong Buy011
Buy111
Hold000
Sell000
Strong Sell000
Total122

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Raymond James
Raymond James
Strong Buy
Initiates
$23
Strong BuyInitiates$23+416.85%Sep 3, 2025
William Blair
William Blair
Buy
Initiates
n/a
BuyInitiatesn/an/aApr 8, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.72
from -10.44
EPS Next Year
-2.54
from -3.72
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
-----27.20M
Revenue Growth
------
EPS
-3.48-2.42-10.44-3.72-2.54-1.07
EPS Growth
------
Forward PE
------
No. Analysts
---665
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
Highn/an/a
Avgn/an/a
Lown/an/a

Revenue Growth

Revenue Growth202520262027
High--
Avg--
Low--

EPS Forecast

EPS202520262027
High-2.79-2.14
Avg-3.72-2.54
Low-4.44-2.74

EPS Growth

EPS Growth202520262027
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.